Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials

There is robust evidence that the appropriate treatment of dyslipidaemia substantially reduces cardiovascular disease-related morbidity and mortality. Raloxifene is a selective oestrogen receptor modulator that also interferes with the lipid metabolism and may be of aid in the management of lipid abnormalities in females. Therefore, we conducted a systematic review and meta-analysis of the available randomized clinical trials (RCTs) exploring the effect of raloxifene on the lipid profile in women. The Scopus, Web of Science, PubMed/Medline and EMBASE databases were systematically and independently searched by two assessors from inception until 20 November 2020 without time and language restrictions. The overall findings were generated from 30 eligible RCTs. As compared to controls, raloxifene resulted in a significant elevation of the high-density lipoproteincholesterol (HDL-C) (WMD: 2.41 mg/dL, 95% CI: 0.84-3.97, P = 0.003) and a significant reduction of the total cholesterol (TC) (WMD: -14.84 mg/dL, 95% CI: -20.37 to -9.317, P = 0.000) and of the low-density lipoprotein-cholesterol (LDL-C) (WMD: 17 mg/dL, 95% CI: -25.77, -8.22, P = 0.000). In the stratified analysis, a significant decrease of serum triglycerides (TG) (WMD: 22.06 mg/dL) was achieved in the RCTs with a duration of <= 26 weeks (WMD 8.70 mg/dL) and with baseline TG concentrations of <= 130 mg/dL (WMD: -23.02 mg/ dL). In conclusion, raloxifene treatment can increase HDL-C and lower LDL-C and TC. In terms of TG, a significant decrease can be observed if the administration of raloxifene lasts <= 26 weeks and if the baseline TG concentrations are <= 130 mg/dL.

Automated summary

The study found that raloxifene can significantly increase high-density lipoprotein cholesterol levels in women, while significantly reducing total cholesterol and low-density lipoprotein cholesterol levels. Additionally, a significant decrease in serum triglycerides levels can be observed with raloxifene treatment duration of <= 26 weeks and baseline TG concentrations of <= 130 mg/dL.